1285539-67-4

Basic information

• Product Name: 5-amino-2-ethoxy-N-(4-methoxyphenyl)benzamide
• Synonyms: 5-amino-2-ethoxy-N-(4-methoxyphenyl)benzamide
• CAS NO: 1285539-67-4
• Molecular Weight: 286.331
• Mol File: 1285539-67-4.mol

Chemical Properties

• CAS DataBase Reference: 5-amino-2-ethoxy-N-(4-methoxyphenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-2-ethoxy-N-(4-methoxyphenyl)benzamide(1285539-67-4)
• EPA Substance Registry System: 5-amino-2-ethoxy-N-(4-methoxyphenyl)benzamide(1285539-67-4)

Safety Data

• Hazardous Substances Data: 1285539-67-4(Hazardous Substances Data)

Upstream product

• 57148-23-9 2-ethoxy-5-nitro-benzoic acid 
• 104-94-9 4-methoxy-aniline 
• 90537-40-9 2-ethoxy-5-nitrobenzoyl chloride 
• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 
• 96-97-9 5-nitrosalicylic acid 
• 80074-34-6 2-ethoxy-5-nitro-benzoic acid methyl ester 
• 1285539-46-9 2-ethoxy-N-(4-methoxyphenyl)-5-nitrobenzamide 

Relevant articles and documents

Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site

PTP1B serving as a key negative regulator of insulin signaling is a novel target for type 2 diabetes and obesity. Modification at ring B of N-{4-[(3-Phenyl-ureido)-methyl]-phenyl}-methane-sulfonamide template to interact with residues Arg47 and Lys41 in t

5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-(4-methoxy-phenyl)-benzamide new compound and preparation method and application thereof

The invention provides a new compound. The name of the compound is 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-(4-methoxy-phenyl)-benzamide; molecular weight of the compound is 600.6; and structure of the compound is as shown in the str

Design and Synthesis of Novel Cyclooxygenase-1 Inhibitors as Analgesics: 5-Amino-2-ethoxy-N-(substituted-phenyl)benzamides

We previously found that N-(4-aminophenyl)-4-trifluoromethylbenzamide (TFAP), a COX-1 inhibitor, exhibits an analgesic effect without causing gastric damage. Unfortunately, TFAP causes reddish purple coloration of urine, and its analgesic effect is less potent than that of indomethacin. Herein we describe our study focusing on the development of 4- and 5-amino-2-alkoxy-N-phenylbenzamide scaffolds, designed on the basis of the structures of TFAP and parsalmide, another known COX-1 inhibitory analgesic agent. 5-Amino-2-ethoxy-N-(2- or 3-substituted phenyl)benzamide derivatives exhibited analgesic activity in a murine acetic acid induced writhing test. Among these compounds, 5-amino-2-ethoxy-N-(2-methoxyphenyl)benzamide (9v) possesses potent COX-1 inhibitory and analgesic activities, similar to those of indomethacin. In addition, 5-amino-2-ethoxy-N-(3-trifluoromethylphenyl)benzamide (9g) showed a more potent analgesic effect than indomethacin or 9v without causing apparent gastric damage or coloration of urine, although its COX-1 inhibitory activity was weaker than that of indomethacin or 9v. Thus, 9g and 9v appear to be promising candidates for analgesic agents and are attractive lead compounds for further development of COX-1 inhibitors.